{"publication_id":"1c0cf558-f04c-47e1-912b-a4da95e9a2f6","screening":{"identified":14,"screened":14,"excluded":0,"included":14,"included_or_retained":14,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"14 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Positive study-level signals are summarized in the immune and inflammation outcome class; null signals are summarized in the contextual adjacent evidence, deficiency prevalence, and immune and inflammation outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","The conclusion is that sirtuin biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.","Finally, the corpus carries a mechanism-to-clinic gap that is structural rather than incidental. The preclinical and in-vitro sources (Cao 2022 NR gavage at 400 mg/kg/day in mice; Ding 2021 multiple-myeloma cell lines; Fu 2022 cisplatin-nephrotoxicity murine model at 8 mg/kg/week; Tsai 2021 pancreatic adenocarcinoma models with 125 mg/kg luciferin; Patyal 2024 SIRT1-v1 transfection in n = 3) supply the dominant mechanistic plausibility, while the human evidence (Wasserfurth 2021, Hwang 2020, Biscetti 2024, Sayedyousef 2025, Moin 2026, Nyarady 2020, Gonzalez-Fernandez 2019, Nowak-Szwed 2025) is almost entirely indirect, with directness flagged as 'indirect' on every source that reports it. There is no source in the corpus that traces a chain from a defined sirtuin intervention in a non-diabetic adult to a hard clinical endpoint, and the only review-design source (Moin 2026) is a meta-analysis of SIRT1 polymorphisms in diabetic nephropathy rather than of sirtuin pharmacodynamics. The synthesis therefore cannot answer whether sirtuin biomarker changes are causes, consequences, or epiphenomena of the cardiometabolic, immune, and periodontal processes the sources describe.","For sirtuin biomarker effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 14 curated reference papers, the evidence base for Sirtuin shows a context-dependent profile. Positive signals appear in: immune. Null findings dominate: contextual other, immune inflammation. The Sirtuin anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}